New Triple-Acting Peptide Drug Outperforms Semaglutide and Tirzepatide for Weight Loss and Atherosclerosis in Mice

The lead candidate UTG-4, a stapled triple agonist targeting GLP-1R/GIPR/GCGR, demonstrated enhanced efficacy over semaglutide (GLP-1R monoagonist) and tirzepatide (GLP-1R/GIPR dual agonist) in obese mice across multiple endpoints: weight loss, food intake suppression, glucose tolerance, and liver health. In Apoe knockout mice (a model of atherosclerosis), UTG-4 showed remarkable anti-atherosclerotic effects. Mechanistically, UTG-4 alleviated endothelial-to-mesenchymal transition in human aortic endothelial cells — a key process driving atherosclerosis progression. The peptide achieved balanced bioactivity across all three receptor targets comparable to their native ligands, with improved pharmacokinetic properties.

Researchers used a solid-phase Ugi macrocyclization strategy to synthesize stapled peptides with a side-chain protractor (for long-acting duration) attached to the exocyclic lactam bridge. They tested receptor activation using bioactivity assays, assessed pharmacokinetics, and evaluated efficacy in diet-induced obese mice (comparing to semaglutide and tirzepatide) and Apoe knockout mice (atherosclerosis model). Mechanistic studies used human aortic endothelial cells to assess endothelial-to-mesenchymal transition.

The race to build on GLP-1 drug success is one of the biggest stories in pharmaceutical development. Triple agonists represent the next frontier — adding glucagon receptor activation to the GLP-1/GIP dual agonism of tirzepatide. If UTG-4's superiority over both semaglutide and tirzepatide translates to humans, it could become the most potent anti-obesity peptide drug yet. The atherosclerosis benefit adds a cardiovascular dimension that goes beyond weight loss alone.

The GLP-1 drug revolution has progressed from monoagonists (semaglutide/liraglutide) to dual agonists (tirzepatide) and is now moving toward triple agonists. Retatrutide (Eli Lilly's triple agonist) is already in late-stage clinical trials. UTG-4 enters this landscape with a novel stapled peptide chemistry and the added benefit of atherosclerosis reduction. The cardiovascular angle is particularly significant, as many obese patients are at high risk for heart disease, and showing that a single peptide can address both metabolic and vascular pathology is a compelling therapeutic proposition.

This is a preclinical mouse study — the efficacy advantages over semaglutide and tirzepatide in mice may not translate proportionally to humans. No human safety or efficacy data exist for UTG-4. The atherosclerosis model (Apoe knockout) is a genetic model that may not perfectly replicate human disease. Specific quantitative outcomes (percent weight loss, dose levels) were not detailed in the abstract. Long-term safety of simultaneous triple receptor activation is unknown.